Medtronic (NYSE: MDT) reported first-quarter fiscal 2027 adjusted earnings per share of $1.45, surpassing the analyst consensus estimate of $1.39 by 4.32 percent.

The medical technology giant also posted quarterly sales of $9.756 billion, beating the consensus estimate of $9.545 billion. Sales rose 13.73 percent from $8.578 billion in the same period last year, while earnings per share increased 15.08 percent from $1.26 per share.

What the Numbers Show

The divergence between revenue growth and earnings growth highlights improved operational efficiency or margin expansion during the quarter. While revenue grew 13.73 percent, adjusted EPS grew at a faster clip of 15.08 percent. This suggests that cost management or favorable mix shifts contributed to profitability beyond simple volume growth.

Furthermore, the company beat both revenue and earnings estimates, indicating stronger-than-expected demand or execution in its core markets. The 2.21 percent beat on sales and 4.32 percent beat on EPS suggest robust underlying business momentum. Analysts noted that non-GAAP gross margin expanded to 65.2%, topping the consensus estimate of 64.8%.

Portfolio Growth Drivers

Cardiovascular sales grew 19.5%, or 18.9% organically, to $3.927 billion. Cardiac Rhythm Management sales rose 15%, while Cardiac Ablation Solutions surged 88%. Neuroscience revenue climbed 10.3%, or 9.3% organically, to $2.678 billion. Cranial and Spinal Technologies grew 13%, including low-20s growth in enabling technology. Altaviva also helped drive 15% growth in Pelvic Health.

Medical Surgical sales increased 10%, or 10.2% organically, to $2.279 billion. Surgical sales rose 9%, while Acute Care & Monitoring grew 14%. Diabetes revenue increased 16.9%, or 14.9% organically, to $843 million.

Fiscal 2027 Outlook Raised

Medtronic raised its fiscal 2027 adjusted earnings guidance from $5.90-$6 per share to $5.94-$6 per share. The new range compares with the $5.95 consensus estimate. The company also lifted its organic revenue growth forecast to 7.25% to 7.75%, up from its previous range of 6.75% to 7.25%.

For the second quarter, Medtronic expects adjusted earnings of $1.32 to $1.34 per share. The midpoint falls below the consensus estimate of $1.34.

Strategic Investments in Robotics and Structural Heart

Medtronic announced an approximately $700 million strategic investment in Cornerstone Robotics. The agreement includes rights to distribute Cornerstone’s Sentire Surgical System in select markets outside the U.S. where it has regulatory approval. Medtronic plans to offer Sentire alongside its Hugo robotic-assisted surgery system. Sentire has received market approval in China, the European Union and Singapore. Management expects Cornerstone to start contributing to growth in fiscal year 2028.

Additionally, Medtronic agreed to invest up to $80 million in Pi-Cardia. The company expects to become the exclusive global distributor of Pi-Cardia’s FDA-cleared ShortCut device in 2027. ShortCut supports complex valve-in-valve transcatheter aortic valve replacement procedures. The agreement gives Medtronic an option to acquire Pi-Cardia after it meets certain milestones. The estimated upfront acquisition price could reach $210 million, plus potential earn-out payments.

Analyst Reactions and Stock Performance

Following the earnings announcement, several analysts adjusted their outlooks for Medtronic:

• Baird analyst David Rescott maintained a Neutral rating and raised the price target from $91 to $100.
• Stifel analyst Rick Wise maintained a Hold rating and raised the price target from $80 to $95.
• BTIG analyst Ryan Zimmerman reiterated a Buy rating, raising the price target from $91 to $100.
• RBC Capital Markets analyst Kendall Au maintained an Outperform rating and price target of $118.
• Needham analyst Mike Matson reaffirmed a Buy rating and price target of $114.

Medtronic shares rose 1.86% to $93.75 in early trading on Wednesday, reversing earlier pre-market declines.

Geoff Martha, Medtronic chairman and chief executive officer, stated: “We are off to a strong start in fiscal 2027. What gives us confidence is not simply the strength of the quarter, but importantly, the breadth of performance across our businesses and the increasing contributions from newer growth platforms.”

Medtronic (NYSE: MDT) issued second-quarter adjusted earnings per share guidance ranging from $1.32 to $1.34. This range aligns with the $1.34 analyst estimate, indicating the company expects to meet market expectations at the upper end of its projection.

The guidance suggests management views the current operational environment as stable relative to prior consensus views. By setting the top of the range at the exact level of analyst estimates, Medtronic signals confidence in achieving baseline profitability targets without signaling significant upside surprise or downside risk in this specific metric.

What the Numbers Show

The alignment between the upper bound of the guided range and the analyst estimate indicates a convergence of internal management forecasts and external market consensus. There is no divergence between the two figures, suggesting that recent operational developments have been fully priced into current market expectations for the quarter.